Figure 2.

Increased expression of ITGB6 was associated with poor clinical outcomes in TCGA data. A – Expression level of ITGB6 in cancer and normal tissues (PAAD: pancreatic adenocarcinoma; ^*p < 0.05). B – Overall survival (OS) and disease-free survival (DFS) rates with ITGB6 expression in TCGA pancreatic adenocarcinoma data: high ITGB6 expression group (n = 89) was significantly associated with lower cancer OS rate and disease-free survival rate compared with low expression group (n = 89; p = 0.025 and p = 0.041, respectively)